Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00072163 · ClinicalTrials.gov registry record · Phase 2

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

A Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT00072163: Completed Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).

NCT00072163 is a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00072163, a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells

Primary Outcome

90% confidence intervals will be used.

Conditions Studied

Recurrent Melanoma Stage IV Melanoma Tumors Metastatic to Brain

Interventions

  • DRUG temozolomide
  • DRUG thalidomide

Study Locations (1)

Illinois

  • Cancer and Leukemia Group B - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2003-10
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00072163 record still lists

NCT00072163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower).

The record links to 3 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.

NCT00072163 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00072163 about?

NCT00072163 is a clinical study titled "Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma". This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thali...

What is the current status of trial NCT00072163?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-10.

What conditions does trial NCT00072163 study?

This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain.

What interventions are being tested in trial NCT00072163?

The interventions under investigation include: temozolomide (DRUG), thalidomide (DRUG).

Who is sponsoring clinical trial NCT00072163?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00072163 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00072163's enrollment target sits among peer trials

50 11th of 23 higher than 12 of 23 other Recurrent Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00072163, the US trial registry maintained by the National Library of Medicine. NCT00072163 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.